Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 354

1.

Morphometricity as a measure of the neuroanatomical signature of a trait.

Sabuncu MR, Ge T, Holmes AJ, Smoller JW, Buckner RL, Fischl B; Alzheimer's Disease Neuroimaging Initiative.

Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):E5749-56. doi: 10.1073/pnas.1604378113. Epub 2016 Sep 9.

2.

Polygenic risk of Alzheimer disease is associated with early- and late-life processes.

Mormino EC, Sperling RA, Holmes AJ, Buckner RL, De Jager PL, Smoller JW, Sabuncu MR; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2016 Aug 2;87(5):481-8. doi: 10.1212/WNL.0000000000002922. Epub 2016 Jul 6.

PMID:
27385740
3.

Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis.

Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC; Alzheimer’s Disease Neuroimaging Initiative.

Nat Commun. 2016 Jun 21;7:11934. doi: 10.1038/ncomms11934.

4.

A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer's disease.

Liu H, Zhou X, Jiang H, He H, Liu X; Alzheimer’s Disease Neuroimaging Initiative.

Sci Rep. 2016 Jun 7;6:26712. doi: 10.1038/srep26712.

5.

Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.

Tan L, Wang HF, Tan MS, Tan CC, Zhu XC, Miao D, Yu WJ, Jiang T, Tan L, Yu JT; Alzheimer’s Disease Neuroimaging Initiative.

Sci Rep. 2016 May 27;6:26027. doi: 10.1038/srep26027.

6.

Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology.

Insel PS, Mattsson N, Mackin RS, Schöll M, Nosheny RL, Tosun D, Donohue MC, Aisen PS, Jagust WJ, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2016 May 17;86(20):1887-96. doi: 10.1212/WNL.0000000000002683. Epub 2016 Apr 15.

PMID:
27164667
7.

Kinetics of the tau PET tracer 18F-AV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment and Alzheimer's disease.

Shcherbinin S, Schwarz AJ, Joshi AD, Navitsky M, Flitter M, Shankle WR, Devous MD Sr, Mintun MA.

J Nucl Med. 2016 May 5. pii: jnumed.115.170027. [Epub ahead of print]

PMID:
27151986
8.

The impact of PICALM genetic variations on reserve capacity of posterior cingulate in AD continuum.

Xu W, Wang HF, Tan L, Tan MS, Tan CC, Zhu XC, Miao D, Yu WJ, Jiang T, Tan L, Yu JT; Alzheimer’s Disease Neuroimaging Initiative Group.

Sci Rep. 2016 Apr 27;6:24480. doi: 10.1038/srep24480.

9.

Better verbal memory in women than men in MCI despite similar levels of hippocampal atrophy.

Sundermann EE, Biegon A, Rubin LH, Lipton RB, Mowrey W, Landau S, Maki PM; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2016 Apr 12;86(15):1368-76. doi: 10.1212/WNL.0000000000002570. Epub 2016 Mar 16.

PMID:
26984945
10.

The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume.

Lupton MK, Strike L, Hansell NK, Wen W, Mather KA, Armstrong NJ, Thalamuthu A, McMahon KL, de Zubicaray GI, Assareh AA, Simmons A, Proitsi P, Powell JF, Montgomery GW, Hibar DP, Westman E, Tsolaki M, Kloszewska I, Soininen H, Mecocci P, Velas B, Lovestone S; Alzheimer's Disease Neuroimaging Initiative, Brodaty H, Ames D, Trollor JN, Martin NG, Thompson PM, Sachdev PS, Wright MJ.

Neurobiol Aging. 2016 Apr;40:68-77. doi: 10.1016/j.neurobiolaging.2015.12.023. Epub 2016 Jan 11.

PMID:
26973105
11.

Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI.

Landau SM, Horng A, Fero A, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2016 Apr 12;86(15):1377-85. doi: 10.1212/WNL.0000000000002576. Epub 2016 Mar 11.

PMID:
26968515
12.

Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.

Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, Joshi AD, Devous MD Sr, Mintun MS.

Brain. 2016 May;139(Pt 5):1539-50. doi: 10.1093/brain/aww023. Epub 2016 Mar 2.

PMID:
26936940
13.

Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.

Podhorna J, Krahnke T, Shear M, Harrison JE; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2016 Feb 12;8:8. doi: 10.1186/s13195-016-0170-5.

14.

Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment.

Shokouhi S, Mckay JW, Baker SL, Kang H, Brill AB, Gwirtsman HE, Riddle WR, Claassen DO, Rogers BP; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2016 Jan 15;8:2. doi: 10.1186/s13195-016-0172-3.

15.

Periventricular hyperintensities are associated with elevated cerebral amyloid.

Marnane M, Al-Jawadi OO, Mortazavi S, Pogorzelec KJ, Wang BW, Feldman HH, Hsiung GY; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2016 Feb 9;86(6):535-43. doi: 10.1212/WNL.0000000000002352. Epub 2016 Jan 8.

PMID:
26747881
16.

Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria.

Grundman M, Johnson KA, Lu M, Siderowf A, Dell'Agnello G, Arora AK, Skovronsky DM, Mintun MA, Pontecorvo MJ; 18F-AV-45-A17 Study Group.

Dement Geriatr Cogn Disord. 2016;41(1-2):80-92. doi: 10.1159/000441139. Epub 2016 Jan 8.

PMID:
26745445
17.

Highly adaptive tests for group differences in brain functional connectivity.

Kim J, Pan W; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2015 Oct 22;9:625-39. doi: 10.1016/j.nicl.2015.10.004. eCollection 2015.

18.

Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease?

Teipel S, Grothe MJ; Alzheimer´s Disease Neuroimaging Initiative.

Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):526-36. doi: 10.1007/s00259-015-3222-3. Epub 2015 Nov 10.

PMID:
26555082
19.

MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials.

Hua X, Ching CR, Mezher A, Gutman BA, Hibar DP, Bhatt P, Leow AD, Jack CR Jr, Bernstein MA, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2016 Jan;37:26-37. doi: 10.1016/j.neurobiolaging.2015.09.018. Epub 2015 Oct 19.

20.

A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin.

Deming Y, Xia J, Cai Y, Lord J, Holmans P, Bertelsen S, Holtzman D, Morris JC, Bales K, Pickering EH, Kauwe J, Goate A, Cruchaga C; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2016 Jan;37:208.e1-9. doi: 10.1016/j.neurobiolaging.2015.09.009. Epub 2015 Sep 25.

PMID:
26545630
Items per page

Supplemental Content

Loading ...
Write to the Help Desk